GET DAILY SIGNALSFHLC vs VHT: Weighing Two Leading Health Care ETFs
Key Takeaways
- Both FHLC and VHT are passively managed, market-capitalization-weighted funds tracking nearly identical MSCI U.S. health care indexes, making their exposure profiles almost interchangeable.
- The two ETFs share essentially the same top holdings, led by LLY, JNJ, and ABBV, so differences in returns are driven mainly by cost and minor holding counts rather than strategy.
- FHLC charges a slightly lower expense ratio (0.08%) than VHT (0.09%), a marginal but durable cost advantage for long-term investors.
- VHT offers greater scale, deeper trading liquidity, and a longer track record (launched in 2004), while FHLC launched in 2013.
- Both funds concentrate in pharmaceuticals, biotechnology, and health care equipment, exposing investors to the same sector-level catalysts and risks.
- Tickeron AI Verdict: Given near-identical exposure, FHLC edges ahead on cost efficiency, making it the AI-preferred choice.
Why These Two ETFs Stand Out
For investors seeking broad U.S. health care exposure, the Fidelity MSCI Health Care Index ETF (FHLC) and the Vanguard Health Care ETF (VHT) are two of the most direct competitors available. Both funds track the same MSCI health care index family and hold essentially the same securities, which makes this a pure cost and structure comparison rather than a debate over differing strategies. As health care remains a defensive, innovation-driven corner of the market, understanding the subtle distinctions between these two funds helps investors select the more efficient vehicle for capturing the sector's long-term growth. I also checked this using Tickeron’s AI Screener to see how the funds compare to others in the industry.
A Closer Look at FHLC
FHLC is a passively managed index ETF that seeks to track the MSCI USA IMI Health Care 25/50 Index, which represents the U.S. health care sector across large-, mid-, and small-capitalization companies. The fund holds roughly 330 securities and applies a market-capitalization weighting methodology with a 25/50 concentration constraint designed to limit single-stock and issuer concentration.
Its top holdings are heavily concentrated in large-cap pharmaceuticals and managed care, including LLY (approximately 13%), JNJ (around 8.8%), ABBV, UNH, and MRK. By industry, pharmaceuticals account for roughly 32% of assets, followed by biotechnology (about 22%), health care equipment and supplies (around 19%), and providers and services (about 16%). The fund carries a net expense ratio of 0.08%, among the lowest in the health care category, and launched in October 2013.
VHT in Detail
VHT tracks the MSCI US Investable Market Health Care 25/50 Index, a near-identical benchmark that also spans U.S. large-, mid-, and small-cap health care stocks using market-cap weighting with the same 25/50 concentration rules. The fund holds approximately 420 to 425 securities, giving it a marginally wider small-cap tail than FHLC.
Its largest positions mirror those of FHLC: LLY, JNJ, ABBV, UNH, and MRK dominate, with pharmaceuticals, biotechnology, and equipment making up the bulk of exposure. The fund's expense ratio is 0.09%, and it was launched in January 2004, giving it one of the longest operating histories in the health care ETF space as well as substantial assets under management (AUM) and deep trading liquidity.
The Health Care Sector Landscape
The U.S. health care sector is currently shaped by several powerful, long-duration forces. Innovation in GLP-1 obesity and diabetes treatments, oncology, and gene therapy continues to drive earnings growth for large-cap pharmaceutical and biotechnology names, while an aging population supports structural demand for providers, equipment, and managed care services. At the same time, regulatory scrutiny over drug pricing, Medicare and Medicaid policy shifts, and litigation risk in managed care create recurring headline volatility. Health care's historically defensive characteristics have also attracted capital during periods of broader equity-market uncertainty, though rising interest rates can weigh on the valuation of longer-duration, innovation-heavy holdings. Both FHLC and VHT sit squarely at the center of these catalysts and risks. From what I see, this backdrop makes the cost differences between the funds particularly relevant.
How FHLC and VHT Compare in Performance and Positioning
Because FHLC and VHT track the same index family with near-identical top holdings, their fund performance and relative positioning have moved almost in lockstep across recent weeks and market cycles. Both funds have benefited from the same sector rotation into health care, driven by strong earnings from large-cap pharmaceutical leaders and renewed defensive positioning. Any divergence between the two is typically measured in single basis points and stems from the one-basis-point expense gap and VHT's slightly broader small-cap exposure. Volatility profiles are effectively equivalent, meaning investors choosing between them are selecting a vehicle rather than a distinct investment thesis. I’m watching this closely as the minor cost edge could matter over time.
My Take: The AI Verdict
When two ETFs are as structurally similar as FHLC and VHT, the tiebreaker falls to observable, durable factors rather than short-term price momentum. Tickeron's AI would likely favor FHLC on the basis of its lower expense ratio (0.08% versus 0.09%), which compounds into a measurable cost advantage over long holding periods despite near-identical exposure. While VHT offers marginally greater scale, liquidity, and historical tenure, these benefits are less relevant to a long-term, buy-and-hold investor than recurring cost. The assessment is probabilistic and rooted in cost efficiency and structural alignment rather than any predicted price move.
Refining ETF Research with AI Tools
In my own analysis, I turn to Tickeron’s AI Screener to quickly compare funds like these against peers, applying filters for expense ratios, sector exposure, and historical performance. It helps surface the small but meaningful differences that matter for long-term portfolios without needing to comb through data manually. This kind of tool has become a regular part of how I evaluate similar options.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VHT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for VHT turned positive on October 12, 2026. Looking at past instances where VHT's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on VHT as a result. In 68 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
VHT moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +2.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 252 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 72 cases where VHT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VHT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
VHT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VHT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement